Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 71 to 77 of 77 total matches.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
inhibitors block conversion of xanthine to uric acid.
They are usually preferred for initial treatment ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021 (Issue 1620)
Hepatotoxicity, bradycardia, AV block, macular $109,144.10
(Novartis) ~55% (vs placebo)17 edema, hypertension ...
Most patients with multiple sclerosis (MS) present
with the relapsing-remitting form of the disease.
Pharmacologic treatment usually includes a
disease-modifying drug, corticosteroids for acute
exacerbations, and other drugs for managing
symptoms such as fatigue, depression, and pain.
Early use of disease-modifying therapy has improved
clinical outcomes.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
.21,22
IL-12 AND IL-23 ANTAGONIST — Ustekinumab
(Stelara) is an anti-p40 antibody that blocks ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Comparison Table: Some Oral Antiseizure Medications (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
,
tremor
Rarely: asymptomatic
first-degree AV block (due
to PR interval prolongation),
atrial ...
View the Comparison Table: Some Oral Antiseizure Medications
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e133-40 doi:10.58347/tml.2024.1708b | Show Introduction Hide Introduction
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • May 26, 2025 (Issue 1729)
is reached (see
Table 2).
Adverse Effects – ARBs, like ACE inhibitors, block the
effects of angiotensin II ...
Pharmacologic management of chronic heart failure
(HF) is primarily determined by the patient's left
ventricular ejection fraction (LVEF) and severity of
symptoms. Patients with chronic HF who have an
LVEF ≤40% are considered to have heart failure with
reduced ejection fraction (HFrEF) and those with an
LVEF ≥50% are considered to have heart failure with
preserved ejection fraction (HFpEF). Patients with an
LVEF of 41-49% have heart failure with mildly reduced
or mid-range ejection fraction.
Med Lett Drugs Ther. 2025 May 26;67(1729):81-8 doi:10.58347/tml.2025.1729a | Show Introduction Hide Introduction
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
.
OTHER AGENTS — The sedating antidepressant
mirtazapine (Remeron, and others) blocks
presynaptic alpha2 ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
appetite, and hypertension. Dose-related seizures can occur.
MIRTAZAPINE — Mirtazapine blocks presynaptic ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction